Format

Send to

Choose Destination
Sci Rep. 2019 Sep 19;9(1):13560. doi: 10.1038/s41598-019-49877-5.

Statin use and the risk of colorectal cancer in a population-based electronic health records study.

Author information

1
Programa d'Analítica de Dades en Oncologia, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain.
2
Servei d'Aparell Digestiu, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
3
Grup de Càncer Colorectal, Programa ONCOBELL, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Spain.
4
CIBER Epidemiologia i Salud Pública (CIBERESP), Madrid, Spain.
5
Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain.
6
Departament de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
7
Departament de Patologia i Terapèutica Experimental. Unitat Docent Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain.
8
Servei d'Aparell Digestiu, Hospital de Viladecans, Viladecans, Spain.
9
Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
10
Servei d'Aparell Digestiu, Hospital de Moisés Broggi, Sant Joan Despí, Spain.
11
Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain. rmorros@idiapjgol.org.
12
Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. rmorros@idiapjgol.org.
13
Institut Català de la Salut (ICS), Barcelona, Spain. rmorros@idiapjgol.org.
14
Programa d'Analítica de Dades en Oncologia, Institut Català d'Oncologia, L'Hospitalet de Llobregat, Spain. v.moreno@iconcologia.net.
15
Grup de Càncer Colorectal, Programa ONCOBELL, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet de Llobregat, Spain. v.moreno@iconcologia.net.
16
CIBER Epidemiologia i Salud Pública (CIBERESP), Madrid, Spain. v.moreno@iconcologia.net.
17
Departament de Ciències Clíniques, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain. v.moreno@iconcologia.net.

Abstract

There is extensive debate regarding the protective effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on colorectal cancer (CRC). We aimed to assess the association between CRC risk and exposure to statins using a large cohort with prescription data. We carried out a case-control study in Catalonia using the System for Development of Primary Care Research (SIDIAP) database that recorded patient diseases history and linked data on reimbursed medication. The study included 25 811 cases with an incident diagnosis of CRC between 2010 and 2015 and 129 117 frequency-matched controls. Subjects were classified as exposed to statins if they had ever been dispensed statins. Analysis considering mean daily defined dose, cumulative duration and type of statin were performed. Overall, 66 372 subjects (43%) were exposed to statins. There was no significant decrease of CRC risk associated to any statin exposure (OR = 0.98; 95% CI: 0.95-1.01). Only in the stratified analysis by location a reduction of risk for rectal cancer was observed associated to statin exposure (OR = 0.87; 95% CI: 0.81-0.92). This study does not support an overall protective effect of statins in CRC, but a protective association with rectal cancer merits further research.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center